首页 > 最新文献

Arkhiv patologii最新文献

英文 中文
[Issues of legal responsibility of the pathologist]. 病理学家的法律责任问题。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238504165
V S Chirsky, I V Timofeev, P G Malkov

Medical care refers to a risky type of activity, since as a result of its provision, harm to the patient's health may be caused and prerequisites for the onset of legal (civil, disciplinary, administrative and criminal) liability may arise. The legal liability of a pathologist in the event of an incorrect diagnosis by the attending physician on the basis of an incorrect conclusion of the pathologist may occur due to violations due to low qualifications, frivolity, negligence, failure to comply with the rules, procedures for providing medical care, job descriptions, official duties. If the incorrect conclusion of the pathologist was of an objective nature (for example, in the case of an incorrect interpretation of a diagnostically difficult case), it should go beyond the scope of punishable shortcomings in the activities of the pathologist. The financial responsibility of a pathologist may occur when its burden is placed on a medical organization for harm caused to the life or health of a patient, due to the establishment, among other things, of the legality of the actions (inaction) of a medical worker with whom the medical organization is in an employment relationship. A medical organization, in case of satisfaction of the patient's claims by the court, as a rule, in a regression procedure, may involve the relevant medical worker who caused the harm in the issue of compensation, compensate for their financial and reputational losses. The most important thing in such cases is to resolve the issue of establishing the grounds for bringing a medical worker to responsibility.

医疗保健是一种有风险的活动,因为提供医疗保健可能对病人的健康造成损害,并可能产生法律(民事、纪律、行政和刑事)责任的先决条件。如果主治医生根据病理学家的错误结论作出错误诊断,病理学家的法律责任可能是由于资历低、轻浮、疏忽、未能遵守提供医疗服务的规则、程序、工作描述、公务等违规行为造成的。如果病理学家的错误结论是客观的(例如,在对诊断困难的病例的错误解释的情况下),它应该超出病理学家活动中应受惩罚的缺点的范围。当医疗组织因与该医疗组织有雇佣关系的医务工作者的行为(不作为)的合法性而使病理学家承担损害病人生命或健康的负担时,病理学家的经济责任就可能发生。医疗机构在法院满足患者要求的情况下,通常在回归程序中,可以让造成伤害的相关医务工作者参与赔偿问题,赔偿其经济和名誉损失。在这种情况下,最重要的是解决追究医务工作者责任的理由问题。
{"title":"[Issues of legal responsibility of the pathologist].","authors":"V S Chirsky,&nbsp;I V Timofeev,&nbsp;P G Malkov","doi":"10.17116/patol20238504165","DOIUrl":"https://doi.org/10.17116/patol20238504165","url":null,"abstract":"<p><p>Medical care refers to a risky type of activity, since as a result of its provision, harm to the patient's health may be caused and prerequisites for the onset of legal (civil, disciplinary, administrative and criminal) liability may arise. The legal liability of a pathologist in the event of an incorrect diagnosis by the attending physician on the basis of an incorrect conclusion of the pathologist may occur due to violations due to low qualifications, frivolity, negligence, failure to comply with the rules, procedures for providing medical care, job descriptions, official duties. If the incorrect conclusion of the pathologist was of an objective nature (for example, in the case of an incorrect interpretation of a diagnostically difficult case), it should go beyond the scope of punishable shortcomings in the activities of the pathologist. The financial responsibility of a pathologist may occur when its burden is placed on a medical organization for harm caused to the life or health of a patient, due to the establishment, among other things, of the legality of the actions (inaction) of a medical worker with whom the medical organization is in an employment relationship. A medical organization, in case of satisfaction of the patient's claims by the court, as a rule, in a regression procedure, may involve the relevant medical worker who caused the harm in the issue of compensation, compensate for their financial and reputational losses. The most important thing in such cases is to resolve the issue of establishing the grounds for bringing a medical worker to responsibility.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9981216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Lung pathology in post-covid syndrome]. [新冠肺炎后综合征的肺部病理学]。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238505152
S N Bugrov, I V Dvorakovskaya, B M Ariel

The clinic and pathological anatomy of the infection caused by the SARS-CoV-2 virus (coronavirus infection - CI) with the development of Post-Covid syndrome (PS) have not been studied enough. This also applies to morphofunctional changes in the lungs, one of the most important components of PS. We conducted a histological and bacterioscopic study of lung biopsy specimens in 20 patients of both sexes aged 22-75 years. In many patients, PS developed relatively late - not earlier than 1 year - 1 year 4 months after the onset of acute clinical symptoms of CI. Structural changes in the lungs in PS appear as an inflammatory reaction such as interstitial pneumonia. Most patients had nonspecific interstitial pneumonia with elements of organizing interstitial pneumonia, in some cases complicated by the presence of a specific granulomatous reaction, characteristic of pulmonary tuberculosis. Despite this, according to the results of traditional bacterioscopic and bacteriological studies, the tuberculous etiology of pulmonary fibrosis has not yet been confirmed. Perhaps this is due to the fact that we are talking about an inapparent tuberculosis infection, the causative agent of which is the L-form of Mycobacterium tuberculosis. Patients with PS who have pulmonary fibrosis on x-ray should be under the special supervision of a phthisiatrician or pulmonologist.

严重急性呼吸系统综合征冠状病毒2型病毒(冠状病毒感染-CI)引起的感染伴随着感染后综合征(PS)的发展,其临床和病理解剖尚未得到足够的研究。这也适用于肺的形态功能变化,肺是PS最重要的组成部分之一。我们对20名22-75岁的男女患者的肺活检标本进行了组织学和细菌学研究。在许多患者中,PS的发展相对较晚,不早于CI急性临床症状发作后1年-1年4个月。PS肺部的结构变化表现为炎症反应,如间质性肺炎。大多数患者患有非特异性间质性肺炎,并伴有组织性间质性疾病,在某些情况下,还伴有肺结核特有的肉芽肿性反应。尽管如此,根据传统的细菌学和细菌学研究结果,肺纤维化的结核病因尚未得到证实。也许这是因为我们谈论的是一种隐性结核病感染,其病原体是结核分枝杆菌的L型。在x光检查中患有肺纤维化的PS患者应在肺结核学家或肺科医生的特别监督下。
{"title":"[Lung pathology in post-covid syndrome].","authors":"S N Bugrov,&nbsp;I V Dvorakovskaya,&nbsp;B M Ariel","doi":"10.17116/patol20238505152","DOIUrl":"10.17116/patol20238505152","url":null,"abstract":"<p><p>The clinic and pathological anatomy of the infection caused by the SARS-CoV-2 virus (coronavirus infection - CI) with the development of Post-Covid syndrome (PS) have not been studied enough. This also applies to morphofunctional changes in the lungs, one of the most important components of PS. We conducted a histological and bacterioscopic study of lung biopsy specimens in 20 patients of both sexes aged 22-75 years. In many patients, PS developed relatively late - not earlier than 1 year - 1 year 4 months after the onset of acute clinical symptoms of CI. Structural changes in the lungs in PS appear as an inflammatory reaction such as interstitial pneumonia. Most patients had nonspecific interstitial pneumonia with elements of organizing interstitial pneumonia, in some cases complicated by the presence of a specific granulomatous reaction, characteristic of pulmonary tuberculosis. Despite this, according to the results of traditional bacterioscopic and bacteriological studies, the tuberculous etiology of pulmonary fibrosis has not yet been confirmed. Perhaps this is due to the fact that we are talking about an inapparent tuberculosis infection, the causative agent of which is the L-form of Mycobacterium tuberculosis. Patients with PS who have pulmonary fibrosis on x-ray should be under the special supervision of a phthisiatrician or pulmonologist.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oleko Dmitrievich Mishnev. (On the occasion of the 80th anniversary of his birth) 奥列科·德米特里耶维奇·米什涅夫。(在他诞辰80周年之际)
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238504184
{"title":"Oleko Dmitrievich Mishnev. (On the occasion of the 80th anniversary of his birth)","authors":"","doi":"10.17116/patol20238504184","DOIUrl":"https://doi.org/10.17116/patol20238504184","url":null,"abstract":"","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67406942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland]. 甲状腺嗜酸性粒细胞增多的硬化性黏液表皮样癌。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238506147
A Yu Abrosimov, E V Bondarenko, D A Pastuhova, M E Beloshitsky

Sclerosing mucoepidermoid carcinoma with stromal eosinophilia of thyroid gland is represented less than 100 cases in the world literature. We present a rare case of sclerosing mucoepidermoid carcinona with stromal eosinophilia in a 69-year-old woman who has been observed for multinodular goiter for more than 3 years. Cytological examination revealed a picture most of all corresponding to a malignant neoplasm (Bethesda V). The patient underwent a thyroidectomy. Pathomorphological examination revealed a neoplasm of mixed structure with foci of cribriform structures and squamous metaplasia with areas of keratinization. According to the IHC study, the expression of TTF-1, p63, cytokeratins 5/6 were positive, while there were no expression of thyroglobulin with its positive reaction in the thyroid tissue. Additional histochemical staining with Alcian blue revealed a positive reaction with a homogeneous acellular substance of the tumor. A comprehensive morphological study with the use of additional stains made it possible to accurately establish the diagnosis, which will determine the further tactics of managing the patient.

在世界文献中,甲状腺硬化性黏液表皮样癌伴间质嗜酸性粒细胞增多的病例不足100例。我们报告一例罕见的硬化性黏液表皮样癌伴间质嗜酸性粒细胞增多的病例,患者为69岁的女性,因多结节性甲状腺肿而被观察超过3年。细胞学检查显示的图像大部分与恶性肿瘤相对应(Bethesda V)。患者接受了甲状腺切除术。病理形态学检查显示一混合结构的肿瘤,有筛状结构和鳞状化生伴角化区。免疫组化研究显示TTF-1、p63、细胞角蛋白5/6表达阳性,甲状腺组织未见甲状腺球蛋白阳性表达。另外用阿利新蓝进行组织化学染色,发现肿瘤与一种均匀的脱细胞物质呈阳性反应。使用额外的染色进行全面的形态学研究,可以准确地建立诊断,这将决定管理患者的进一步策略。
{"title":"[Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland].","authors":"A Yu Abrosimov, E V Bondarenko, D A Pastuhova, M E Beloshitsky","doi":"10.17116/patol20238506147","DOIUrl":"10.17116/patol20238506147","url":null,"abstract":"<p><p>Sclerosing mucoepidermoid carcinoma with stromal eosinophilia of thyroid gland is represented less than 100 cases in the world literature. We present a rare case of sclerosing mucoepidermoid carcinona with stromal eosinophilia in a 69-year-old woman who has been observed for multinodular goiter for more than 3 years. Cytological examination revealed a picture most of all corresponding to a malignant neoplasm (Bethesda V). The patient underwent a thyroidectomy. Pathomorphological examination revealed a neoplasm of mixed structure with foci of cribriform structures and squamous metaplasia with areas of keratinization. According to the IHC study, the expression of TTF-1, p63, cytokeratins 5/6 were positive, while there were no expression of thyroglobulin with its positive reaction in the thyroid tissue. Additional histochemical staining with Alcian blue revealed a positive reaction with a homogeneous acellular substance of the tumor. A comprehensive morphological study with the use of additional stains made it possible to accurately establish the diagnosis, which will determine the further tactics of managing the patient.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Causes of death in the Moscow region according to medical death certificates]. [根据医学死亡证明,莫斯科地区的死亡原因]。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238501129
E P Kakorina, I V Samorodskaya, T K Chernyavskaya

Objective: Determination of the leading causes of death based on data from primary medical death certificates (MDCs) depending on the place of death.

Material and methods: From the electronic database of the Main Department of the Civil Registry Office of the Moscow Region (the USR registry office system) for 2021, all cases were selected in which diseases were indicated as the primary cause of death (PCD); all codes of external causes, injuries and poisonings were excluded. A total of 109.126 cases, 50.6% died in the hospital, 34% died at home, and 16.4% died elsewhere. Bureau of Forensic Medical Examination (BFME) issued 45.2% of MSS. Taking into account the frequency of use of ICD codes, the clinical similarity of individual codes, 20 groups were formed, which accounted for 90.1% of deaths from diseases.

Results: The frequency of registration of individual groups of causes of death largely depends on the place of death. 5 leading groups of causes of death were established: 1) in general from COVID-19 23.55%, chronic ischemic heart disease (CIHD-1) without postinfarction cardiosclerosis, aneurysm and ischemic cardiomyopathy (CMP) 14.5%, from encephalopathy indefinite (EI) 11.4%, malignant neoplasms (MN) 11.3%, stroke 6.2%; 2) in a hospital from COVID-19 45%, stroke 10%, MN 8.3%; CIHD-1 7.1%, CIHD with a history of MI/ischemic CMP 2.7%; 3) at home from CIHD-1 21.8%, EI 21.5%, MN 15.5%, from diseases associated with alcohol 3.3% and brain cyst 3.3%; 4) elsewhere from CIHD-1 22.7%, EI 21.6%, MN 12%, from other forms of acute coronary artery disease 5.4%, alcohol-associated diseases 4.8%. Acute MI ranked 6th among deaths in general - 2.7%. PCD is also associated with the place of issue of the MDCs - 90% of the MDC with the indication of EI and «other degenerative diseases of the nervous system» as the cause of death were issued by the BFME. Not a single MDC issued by the BFME contained such PCDs as "old age" or "brain cyst".

Conclusion: The nosological structure of the causes of death and the issuance of individual ICD codes in the MDC as a PCD varies significantly depending on the place of death and the issuance of the MDC. The reasons need to be further clarified. The use of codes that are not permitted for use has been registered.

目的:根据主要医疗死亡证明(MDCs)的数据,根据死亡地点确定主要死亡原因。材料和方法:从2021年莫斯科州民事登记办公室(USR登记办公室系统)主要部门的电子数据库中选择所有病例,其中疾病被指定为主要死亡原因(PCD);所有外因、伤害和中毒的代码都被排除在外。共109.126例,其中医院死亡50.6%,家中死亡34%,其他地方死亡16.4%。法医检验局签发了45.2%的MSS。考虑到ICD编码的使用频率、个体编码的临床相似性,共形成20组,占疾病死亡人数的90.1%。结果:各组死亡原因的登记频率在很大程度上取决于死亡地点。确定5组主要死亡原因:1)一般死于新冠肺炎23.55%,无梗死后心硬化、动脉瘤和缺血性心肌病(CMP)的慢性缺血性心脏病(CIHD-1) 14.5%,不明确脑病(EI) 11.4%,恶性肿瘤(MN) 11.3%,脑卒中6.2%;2)住院时患COVID-19的占45%,卒中占10%,MN占8.3%;CIHD-1 7.1%,伴有MI/缺血性CMP病史的CIHD 2.7%;3)家中来自CIHD-1的21.8%,EI的21.5%,MN的15.5%,酒精相关疾病的3.3%,脑囊肿的3.3%;4)其他来自CIHD-1的22.7%,EI 21.6%, MN 12%,其他形式的急性冠状动脉疾病5.4%,酒精相关疾病4.8%。急性心肌梗死在总死亡人数中排名第六,占2.7%。PCD还与疾病诊断证明书的签发地有关——90%的疾病诊断证明书显示,EI和"其他神经系统退行性疾病"是由疾病诊断和诊断局签发的死因。BFME发布的MDC中没有一个包含诸如“老年”或“脑囊肿”之类的PCDs。结论:死亡原因的分科结构和MDC作为PCD的个人ICD代码的签发,因死亡地点和MDC的签发而有显着差异。原因需要进一步澄清。对不允许使用的代码进行了注册。
{"title":"[Causes of death in the Moscow region according to medical death certificates].","authors":"E P Kakorina,&nbsp;I V Samorodskaya,&nbsp;T K Chernyavskaya","doi":"10.17116/patol20238501129","DOIUrl":"https://doi.org/10.17116/patol20238501129","url":null,"abstract":"<p><strong>Objective: </strong>Determination of the leading causes of death based on data from primary medical death certificates (MDCs) depending on the place of death.</p><p><strong>Material and methods: </strong>From the electronic database of the Main Department of the Civil Registry Office of the Moscow Region (the USR registry office system) for 2021, all cases were selected in which diseases were indicated as the primary cause of death (PCD); all codes of external causes, injuries and poisonings were excluded. A total of 109.126 cases, 50.6% died in the hospital, 34% died at home, and 16.4% died elsewhere. Bureau of Forensic Medical Examination (BFME) issued 45.2% of MSS. Taking into account the frequency of use of ICD codes, the clinical similarity of individual codes, 20 groups were formed, which accounted for 90.1% of deaths from diseases.</p><p><strong>Results: </strong>The frequency of registration of individual groups of causes of death largely depends on the place of death. 5 leading groups of causes of death were established: 1) in general from COVID-19 23.55%, chronic ischemic heart disease (CIHD-1) without postinfarction cardiosclerosis, aneurysm and ischemic cardiomyopathy (CMP) 14.5%, from encephalopathy indefinite (EI) 11.4%, malignant neoplasms (MN) 11.3%, stroke 6.2%; 2) in a hospital from COVID-19 45%, stroke 10%, MN 8.3%; CIHD-1 7.1%, CIHD with a history of MI/ischemic CMP 2.7%; 3) at home from CIHD-1 21.8%, EI 21.5%, MN 15.5%, from diseases associated with alcohol 3.3% and brain cyst 3.3%; 4) elsewhere from CIHD-1 22.7%, EI 21.6%, MN 12%, from other forms of acute coronary artery disease 5.4%, alcohol-associated diseases 4.8%. Acute MI ranked 6<sup>th</sup> among deaths in general - 2.7%. PCD is also associated with the place of issue of the MDCs - 90% of the MDC with the indication of EI and «other degenerative diseases of the nervous system» as the cause of death were issued by the BFME. Not a single MDC issued by the BFME contained such PCDs as \"old age\" or \"brain cyst\".</p><p><strong>Conclusion: </strong>The nosological structure of the causes of death and the issuance of individual ICD codes in the MDC as a PCD varies significantly depending on the place of death and the issuance of the MDC. The reasons need to be further clarified. The use of codes that are not permitted for use has been registered.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10750093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparison of the efficiency of surgical excision methods for detecting extraprostatic extension and positive resection margin in prostate cancer]. [外科切除方法检测前列腺癌症前列腺外延伸和阳性切除边缘的效率比较]。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238505148
F V Novikov, O S Tesljuk, G D Efremov

On the samples of 26 prostatectomies, the method of excision of the prostate gland according to Kim was tested. This method increased the number of blocks by 30.2% and increased the detectability of extraprostatic extension by 41.7% and positive surgical margin by 40.0% compared to the method of alternate prostate sections. Also, the method according to Kim reduced the number of blocks of prostate tissue by 34.3% compared to the method of complete prostate excision.

在26例前列腺切除术的样本上,测试了Kim提出的前列腺切除方法。与交替前列腺切片的方法相比,该方法将阻断次数增加了30.2%,将前列腺外延伸的可检测性增加了41.7%,将阳性手术切缘增加了40.0%。此外,根据Kim的方法与完全前列腺切除的方法相比,前列腺组织块的数量减少了34.3%。
{"title":"[Comparison of the efficiency of surgical excision methods for detecting extraprostatic extension and positive resection margin in prostate cancer].","authors":"F V Novikov,&nbsp;O S Tesljuk,&nbsp;G D Efremov","doi":"10.17116/patol20238505148","DOIUrl":"10.17116/patol20238505148","url":null,"abstract":"<p><p>On the samples of 26 prostatectomies, the method of excision of the prostate gland according to Kim was tested. This method increased the number of blocks by 30.2% and increased the detectability of extraprostatic extension by 41.7% and positive surgical margin by 40.0% compared to the method of alternate prostate sections. Also, the method according to Kim reduced the number of blocks of prostate tissue by 34.3% compared to the method of complete prostate excision.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Professor Dmitry Egorovich Min - physician and poet]. Dmitry Egorovich Min教授-医生和诗人。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238505173
Yu I Pigolkin, I E Loban, V V Nashenkin, S N Zakharov

Dmitry Egorovich Min is an outstanding pathologist, forensic physician and hygienist of the Russian Empire, a prominent public figure, professor and vice-rector of the Imperial Moscow University, an outstanding poet-translator and one of the founders of the Russian school of forensic medicine. This article discusses the biography of D.E. Min, his merits and accomplishments in labor and creative activity.

德米特里·埃戈罗维奇·敏(Dmitry Egorovich Min)是俄罗斯帝国杰出的病理学家、法医和卫生学家,著名公众人物,莫斯科帝国大学教授和副校长,杰出的诗人翻译家,俄罗斯法医学院的创始人之一。本文论述了闵的生平及其在劳动和创作活动中的功绩和成就。
{"title":"[Professor Dmitry Egorovich Min - physician and poet].","authors":"Yu I Pigolkin,&nbsp;I E Loban,&nbsp;V V Nashenkin,&nbsp;S N Zakharov","doi":"10.17116/patol20238505173","DOIUrl":"10.17116/patol20238505173","url":null,"abstract":"<p><p>Dmitry Egorovich Min is an outstanding pathologist, forensic physician and hygienist of the Russian Empire, a prominent public figure, professor and vice-rector of the Imperial Moscow University, an outstanding poet-translator and one of the founders of the Russian school of forensic medicine. This article discusses the biography of D.E. Min, his merits and accomplishments in labor and creative activity.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors]. [世界卫生组织造血和淋巴组织肿瘤分类,2022(第5版):髓细胞和组织细胞肿瘤]。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238505136
Z P Asaulenko, I N Spiridonov, D V Baram, Yu A Krivolapov

The article reviews the changes in the structure of classification, diagnostic criteria for myeloid and histiocytic neoplasms in the 5th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2022). Information is presented regarding new nosological forms, renaming and abolition of some previously existing ones. The importance of molecular genetic studies in the isolation of myeloid and histiocytic neoplasms and the need to apply these studies in clinical practice are emphasized. Myeloid and histiocytic precancerous and proliferative processes, genetic tumor syndromes, introduced into the classification for the first time, are considered.

本文回顾了世界卫生组织第5版《造血和淋巴组织肿瘤分类》(2022)中髓系和组织细胞肿瘤的分类结构、诊断标准的变化。介绍了关于新的疾病学形式、重命名和废除一些以前存在的形式的信息。强调了分子遗传学研究在分离髓系和组织细胞肿瘤中的重要性,以及将这些研究应用于临床实践的必要性。髓细胞和组织细胞癌前和增殖过程,遗传性肿瘤综合征,首次被纳入分类,被考虑在内。
{"title":"[WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors].","authors":"Z P Asaulenko,&nbsp;I N Spiridonov,&nbsp;D V Baram,&nbsp;Yu A Krivolapov","doi":"10.17116/patol20238505136","DOIUrl":"10.17116/patol20238505136","url":null,"abstract":"<p><p>The article reviews the changes in the structure of classification, diagnostic criteria for myeloid and histiocytic neoplasms in the 5<sup>th</sup> edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2022). Information is presented regarding new nosological forms, renaming and abolition of some previously existing ones. The importance of molecular genetic studies in the isolation of myeloid and histiocytic neoplasms and the need to apply these studies in clinical practice are emphasized. Myeloid and histiocytic precancerous and proliferative processes, genetic tumor syndromes, introduced into the classification for the first time, are considered.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of the textbook «Pathological anatomy» edited by V.S. Paukov M.: GEOTAR-Media; 2022;752 复习教科书«病理解剖»由V.S. Paukov M.编辑:GEOTAR-Media;2022年,752年
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238501179
{"title":"Review of the textbook «Pathological anatomy» edited by V.S. Paukov M.: GEOTAR-Media; 2022;752","authors":"","doi":"10.17116/patol20238501179","DOIUrl":"https://doi.org/10.17116/patol20238501179","url":null,"abstract":"","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67406229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy]. [PD-L1表达与肿瘤干细胞标志物CD44的关系为开发癌症靶向治疗新方法提供了有希望的基础]。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/patol20238506170
T N Sotnikova, T V Polushkina, N V Danilova

Immunotherapy of malignant tumors is a rapidly developing area of oncology. PD-1 is a receptor expressed by activated T-lymphocytes. As a result of its interaction with the ligand (PD-L1 or PD-L2), the activity of T-lymphocytes is inhibited and their apoptosis occurs. Drugs that inhibit the interaction of PD-1 with ligands have an immunostimulatory effect and are effective in the treatment of many types of neoplasms: melanoma, lung cancer, bladder cancer, stomach cancer, various lymphomas, etc. However, response to this treatment is observed only in a narrow cohort of patients. To increase the effectiveness of immunotherapy, combined preparations and nanoparticles are being developed and created to enhance the effect of PD-L1 inhibitors, and containing hyaluronic acid as a ligand for the CD44 protein, which is expressed in many human tumors. However, the issue of co-expression of CD44 and PD-L1 remains poorly understood. This review is devoted to describing the features of co-expression and the mechanisms of interaction between CD44 and PD-L1. Promising directions for the development of new approaches to the immunotherapy of malignant tumors are presented.

恶性肿瘤的免疫治疗是肿瘤学中一个快速发展的领域。PD-1是由活化的t淋巴细胞表达的受体。由于其与配体(PD-L1或PD-L2)的相互作用,t淋巴细胞的活性被抑制并发生凋亡。抑制PD-1与配体相互作用的药物具有免疫刺激作用,可有效治疗多种肿瘤:黑色素瘤、肺癌、膀胱癌、胃癌、各种淋巴瘤等。然而,仅在一小部分患者中观察到对这种治疗的反应。为了提高免疫治疗的有效性,人们正在开发和制造联合制剂和纳米颗粒,以增强PD-L1抑制剂的效果,并含有透明质酸作为CD44蛋白的配体,CD44蛋白在许多人类肿瘤中表达。然而,CD44和PD-L1的共表达问题仍然知之甚少。本文综述了CD44与PD-L1共表达的特点及其相互作用机制。提出了恶性肿瘤免疫治疗新方法的发展前景。
{"title":"[Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].","authors":"T N Sotnikova, T V Polushkina, N V Danilova","doi":"10.17116/patol20238506170","DOIUrl":"10.17116/patol20238506170","url":null,"abstract":"<p><p>Immunotherapy of malignant tumors is a rapidly developing area of oncology. PD-1 is a receptor expressed by activated T-lymphocytes. As a result of its interaction with the ligand (PD-L1 or PD-L2), the activity of T-lymphocytes is inhibited and their apoptosis occurs. Drugs that inhibit the interaction of PD-1 with ligands have an immunostimulatory effect and are effective in the treatment of many types of neoplasms: melanoma, lung cancer, bladder cancer, stomach cancer, various lymphomas, etc. However, response to this treatment is observed only in a narrow cohort of patients. To increase the effectiveness of immunotherapy, combined preparations and nanoparticles are being developed and created to enhance the effect of PD-L1 inhibitors, and containing hyaluronic acid as a ligand for the CD44 protein, which is expressed in many human tumors. However, the issue of co-expression of CD44 and PD-L1 remains poorly understood. This review is devoted to describing the features of co-expression and the mechanisms of interaction between CD44 and PD-L1. Promising directions for the development of new approaches to the immunotherapy of malignant tumors are presented.</p>","PeriodicalId":8548,"journal":{"name":"Arkhiv patologii","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138443683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arkhiv patologii
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1